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Abstract
Background:  Isg15 covalently modifies murine endometrial proteins in response to early
pregnancy. Isg15 can also be severed from targeted proteins by a specific protease called Ubp43
(Usp18). Mice lacking Ubp43 (null) form increased conjugated Isg15 in response to interferon. The
Isg15 system has not been examined in chorioallantoic placenta (CP) or mesometrial (MM)
components of implantation sites beyond 9.5 days post coitum (dpc). It was hypothesized that
deletion of Ubp43 would cause disregulation of Isg15 in implantation sites, and that this would affect
pregnancy rates.
Methods: Heterozygous (het) Ubp43 mice were mated and MM and CP implantation sites were
collected on 12.5 and 17.5 days post-coitum (dpc).
Results: Free and conjugated Isg15 were greater on 12.5 versus 17.5 dpc in MM. Free and
conjugated Isg15 were also present in CP, but did not differ due to genotype on 12.5 dpc. However,
null CP had greater free and conjugated Isg15 when compared to het/wt on 17.5 dpc. Null progeny
died in utero with fetal genotype ratios (wt:het:null) of 2:5:1 on 12.5 and 2:2:1 on 17.5 dpc.
Implantation sites were disrupted within the junctional zone and spongiotrophoblast, contained
less vasculature based on lectin B4 staining and contained greater Isg15 mRNA and VEGF protein
in Ubp43 null when compared to wt placenta.
Conclusion: It is concluded that Isg15 and its conjugates are present in implantation sites during
mid to late gestation and that deletion of Ubp43 causes an increase in free and conjugated Isg15 at
the feto-maternal interface. Also, under mixed genetic background, deletion of Ubp43 results in
fetal death.
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Background
Interferon stimulated gene product 15 (Isg15) is a ubiqui-
tin-like protein that is transiently produced in the uterus
during early pregnancy in several species including pri-
mates [1], ruminants [2-4], pigs [5] and mice [6,7]. Isg15
post-translationally modifies other proteins through cov-
alent attachment using a mechanism that is similar to, yet
distinct from ubiquitinylation. This conjugation (Isgyla-
tion) to target proteins involves three classes of enzymes,
an E1 and several E2s and E3s. Isg15 functions as a ubiq-
uitin homolog to regulate general cellular processes such
as RNA splicing, chromatin remodeling/polymerase II
transcription, cytoskeleton organization and regulation,
stress responses, and translation by conjugating to and
regulating intracellular proteins [8-14]. It also exists in a
non-conjugated form and has been shown to be released
from cells and to have a cytokine-like role [15,16].
Within ruminant species, conceptus (embryo proper and
surrounding membranes)-secreted interferon (IFN)-tau
(τ) interacts with type I IFN receptors on the endometrial
surface to activate the Janus kinase-signal transducers and
activators of transcription (JAK-STAT) signal cascade
[17,18]. Activation of the JAK-STAT pathway leads to the
increased production of Isg15. In mice and humans, a
conceptus-secreted IFN has not been identified, however
Isg15 is up-regulated in the uterus in these species as well
[1,6,7,19,20]. For example, Isg15 is up-regulated 3.9-fold
in human decidualized stromal cells by embryo-secretory
products [20]. Furthermore, induction of Isg15 in mouse
decidua might be due to an interferon-like cytokine that is
released by trophoblast giant cells [7].
Cleavage of ubiquitin from target proteins plays an
important role in numerous biological events such as;
proteasome-mediated protein degradation [21], preim-
plantation embryo development [22], cell growth and dif-
ferentiation [23-25], transcriptional activation [23], and
signal transduction [26]. There are at least five distinct
families of deubiquitinating enzymes with four sub-
families that are commonly referred to as cysteine pro-
teases [27]. Ubiquitin processing proteases (Ubps/Usps)
are the largest and most diverse group within the cysteine
protease subfamilies. Sequence homology is limiting
among Ubps, however short consensus sequences sur-
round conserved cysteine and histidine residue boxes [26-
28]. Diversity in these amino acids may provide specificity
for ubiquitin and ubiquitin-like proteases.
Ubp43 (Usp18) is an Isg15-specific protease [29,30] that
is up-regulated in response to IFN or lipopolysaccharide
[31,32]. Overexpression of Ubp43 in monocyte cells
inhibits cytokine-induced terminal differentiation [29].
Chemistry-based proteomics were used to identify poten-
tial ubiquitin and ubiquitin-like proteases, which
revealed that Ubp43 was specific to Isg15 [33,34].
Mice that survive to birth with a disrupted Ubp43 gene
had increased Isg15 conjugation and a decreased life
expectancy due to hydrocephalus and associated neurode-
generative disease [30]. These data support the require-
ment of proper regulation of Isgylation by Ubp43
cleavage. However, more recent experiments suggest that
Ubp43 regulates IFN signaling independent of its iso-
peptidase activity towards Isg15 [35]. The data indicate
that Ubp43 binds directly to IFN receptor (AR2 subunit)
and inhibits receptor-associated JAK activity. Also, Isg15 -
/- and Isg15 E1 (Ube1L) -/- mice that survived to term
were reported to be viable and fertile and had no obvious
abnormalities [36,37]. Furthermore, the major pheno-
types of Ubp43 deficient mice were not rescued in Isg15/
Ubp43 or Ube1L/Ubp43 double knockout mice [37,38].
Isg15 is localized to antimesometrial decidua during
implantation in mice [6,7]. Implantation, which involves
adhesion of trophoblast with the endometrium that is fol-
lowed by invasion, vascularization and placentation
begins 4.5–7.5 days post-coitum (dpc) on the antimes-
ometrial pole when the decidualized stroma essential
serves as a maternal placenta. The primary adhesion, or
attachment occurs on the avascular antimesometrial pole.
Later, decidualization extends to the vascular mesometrial
pole to facilitate development of the placenta (Figure 1).
We first localized Isg15 to the antimesometrial pole of the
implantation site [6]. Currently, it is unknown if Isg15 is
expressed later than 9.5 dpc in the antimesometrial pole,
or if it also appears in the mesometrial decidua and pla-
centa.
A description of embryo development and implantation
sites in Ubp43 -/- mice is lacking. Because Isg15 and its
conjugates are transiently produced in the uterus during
pregnancy in several mammalian species it was theorized
that placental development and function might be
impaired by Ubp43 deletion. Therefore, the objective was
to determine if altered fetal Ubp43 gene expression in a
heterozygous uterine environment affected the Isg15 sys-
tem of maternal and fetal tissues and whether this resulted
in lowered fetal viability.
Methods
Breeding and tissue collection
Experimental procedures using mice were reviewed and
approved by the University of Wyoming Institutional Ani-
mal Care and Use Committee. Heterozygous (Ubp43+/-)
C57 BL/6 × 129 × Swiss Webster males and females [30]
were mated to produce wild-type (wt), heterozygous (+/-)
and null (-/-) fetuses within a heterozygous uterine envi-
ronment. Presence of a vaginal plug on the morning afterReproductive Biology and Endocrinology 2007, 5:13 http://www.rbej.com/content/5/1/13
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pairings was designated as 0.5 dpc. Tissues were collected
on 12.5 (4 litters; 30 fetuses) or 17.5 (6 litters; 35 fetuses)
dpc. Maternal and fetal tissues consisted of uterine tissue
at the placental interface or mesometrial (MM) tissue,
uterine tissue surrounding the fetus or anti-mesometrial
(AM) tissue, and the fetal-derived placental tissue referred
to as fetal chorioallantoic placenta (CP) (Figure 1).
At the time of tissue collection a portion of fetal tissue was
also collected to determine genotype by PCR techniques.
Briefly, tissue was lysed per DNeasy (Qiagen Inc., Valen-
cia, CA) protocol to acquire genomic DNA. Genotyping
by PCR technique was conducted using the following
primers; Ubp43 exon 2 anti-sense strand, 5'-GCCT-
GGAAGTGAAGTTGTGGACTCCCG-3'; Ubp43 exon 2
sense strand, 5'-CCAGCGTGAGTACTGCTGCGGCTCAG-
3'; and β-galactosidase sense strand, 5'-CGTAACCGT-
GCATCTGCCAGTTTGAGG-3'. Amplification of a 150 bp
fragment resulted from a wt allele and a 370 bp fragment
represented a null allele (data not shown). PCR condi-
tions were; 95°C – 2 minutes; (95°C – 15 seconds, 60°C
– 15 seconds and 72°C – 30 seconds) × 30 cycles; 72°C –
2 minute extension.
Protein analysis
Tissue lysates from maternal (MM and AM tissue 12.5 dpc:
n = 4 wt, 2 het, and 2 null; 17.5 dpc: n = 4 wt, 4 het, and
2 null) and fetal compartments (CP tissue 12.5 dpc: n = 4
wt, 2 het, and 2 null; 17.5 dpc: n = 4 wt, 4 het, and 2 null)
were prepared by homogenizing tissue (100 mg/ml) in 1×
Laemmli buffer [39]. Equal concentrations of lysates
(12.5 μg per lane) were loaded onto 1D-SDS PAGE gels,
electrophoretically transferred to 0.2 μ nitrocellulose and
western blot detection was performed using rabbit poly-
clonal antibodies [anti-mouse Isg15 antibody (1:30,000;
[6], anti-human VEGF antibody (1:500; sc-152, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), anti-mouse
Angiopoietin-1 antibody (1:1,000; ab8451, Abcam Inc.,
Cambridge, MA), anti-mouse VEGF Flt-1 Receptor anti-
body (1:500; sc-316, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), and anti-mouse AMP kinase antibody
(1:1,000; A1475-01B, US Biological, Swampscott, MA)].
Secondary antibodies against rabbit were conjugated to
either alkaline phosphatase or horseradish peroxidase
(Promega, Madison, WI) for visualization of bands. A no-
first antibody was used as a control to identify non-spe-
cific bands. Detection of a secondary antibody reactive
Illustration of fetal development and Ubp43 genotype on day 17.5 of pregnancy (A) and description of how implantation sites  were collected (B) Figure 1
Illustration of fetal development and Ubp43 genotype on day 17.5 of pregnancy (A) and description of how implantation sites 
were collected (B). A litter from a day 17.5 pregnant mouse shows that all Ubp43 null offspring were dead. Genotype ratio was 
2:2:1 (wt:het:null) on day 17.5. On day 12.5, 75% of Ubp43 null mice were dead with a genotype ratio of 2:5:1. There also was 
a significant loss of +/- fetuses between 12.5 and 17.5 suggesting that Ubp43 gene dosage may also be involved. Panel B shows 
a cross-sectional representation of a mouse uterus illustrating the various tissues collected for protein and RNA analysis. Anti-
mesometrial (AM) represents uterine tissue surrounding the fetal compartment. Fetal chorioallantoic placenta (CP) represents 
fetal-derived placental tissue. Mesometrial decidua (MM) represents uterine tissue in direct contact with fetal-derived placenta.
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protein was used to verify loading. No differences were
seen among samples (P > 0.10; data not shown). Immu-
noreactive bands were scanned using UNSCANIT (Silk
Scientific, Orem, UT).
RNA analysis
Tissues from 12.5 dpc (n = 3 wt, 3 het, and 2 null) or 17.5
dpc (n = 3 wt, 2 het, and 2 null) chroioallantoic placenta
were homogenized in Tri Reagent (Molecular Research
Center, Inc., Cincinnati, OH). Seven μg of total RNA from
each sample was loaded per well and separated on a 1.5%
denaturing agarose gel. Separated RNA was transferred to
nitrocellulose by capillary transfer and baked at 80°C for
two hours. Membranes were prehybridized for 3 hours at
42°C in buffer (50% formamide, 5× SSC, 50 mM Na2PO4,
5× Denhardts, 0.1% SDS, 0.1 mg/ml salmon sperm
DNA). Blots were then hybridized in the same buffer with
radiolabeled probe.
A partial murine Isg15 or Ubp43 cDNA was synthesized
using total RNA from pregnant murine uterine tissue and
RT-PCR with the following primers; Isg15 anti-sense
strand, 5'-ATGGCCTGGGACCTAAAGGTG; Isg15 sense
strand, 5'-AAGCTCAGCCAGAACTGGTCT; Ubp43 anti-
sense strand, 5'-ATGGGCAAGGGGTTTG-3'; and Ubp43
sense strand, 5'-TCAGGATCCAGTCTTC-3'. Amplicons
were subcloned into ZeroBlunt (Invitrogen, Carlsbad, CA)
vector and sequenced to confirm identity. Complemen-
tary DNA was radiolabeled using 50 μCi [α-32P]dCTP and
Klenow in a standard random primer labeling reaction.
Northern blots were washed 3×, 5 minutes each at 42°C
(2× SSC/0.1% SDS or 1× SSC/0.1% SDS). Membranes
were exposed to film for 6 days at -80°C. Northern blot
results were normalized to an 18S rRNA band. Autoradio-
grams were scanned and quantitated using UNSCANIT.
Bacterial and viral screening
To verify that the immune system of these mice was not
compromised by bacteria or pathogens we submitted tis-
sue samples to the following accredited facilities for anal-
ysis. Tissue samples from a breeding pair that was housed
in our facility for six months were submitted to the Wyo-
ming State Veterinary Laboratory (Laramie, WY) and sero-
logical samples were submitted to Charles River
Laboratories (Wilmington, MA).
Morphology of day 12.5 implantation sites
Murine implantation sites were fixed in 4 % paraformal-
dehyde, paraffin-embedded, serially sectioned at 6 μm
and then stained with hematoxylin/eosin (H&E) for
standard histological examination. Immunohistochemis-
try was performed with 20 μg/ml of Isolectin B4 antibody
in 0.1% BSA-PBS (Vector Lab) and 20 μg/ml Horseradish
Peroxidase Streptavidin (Vector Lab) as the enzyme conju-
gate. The staining was developed with AEC (Vector Lab)
and counterstained with hematoxylin.
Statistical analysis
To determine differences among genotypes and dpc, data
were analyzed using the General Linearized Model of Sta-
tistical Analysis Systems (SAS, 1998). The effects of geno-
type on concentrations of and expression of free Isg15 and
concentrations of conjugated Isg15 and VEGF were ana-
lyzed using one-way ANOVA, followed by protected pre-
planned t-test (P < 0.05) comparisons.
Results
Genotyping and genetic profile
Fetal development for Ubp43 -/-, -/+ and +/+ offspring is
represented in Figure 1. Genotype ratio was 2:5:1 on day
12.5 and 2:2:1 on day 17.5. All null offspring were dead
on day 17.5, whereas 75% of null offspring were dead on
day 12.5. Several +/- offspring also died between 12.5 and
17.5 dpc. Chi square analysis revealed that genotypic
ratios for live offspring on 12.5 (P < 0.05) and 17.5 dpc (P
< 0.01) did not follow the normal expected mendelian
ratio of 1:2:1.
Expression of Isg15 and Ubp43 in fetal-derived placenta
Northern blot analysis of CP tissue for Isg15 and Ubp43
verified expression of Isg15 in all genotypes (Figure 2).
Ubp43 mRNA was only present in northern blots at the
correct size within wt- and het-derived tissues. Null fetal-
derived tissues containing the beta-galactosidase (lacZ)
reporter had an expected shift in the size of the mRNA
band of approximately 3 kilobases. Null CP tissue had
greater (P < 0.07) expression of Isg15 mRNA regardless of
dpc in contrast to wt or het (Figure 2). All samples were
normalized to an 18S rRNA as a loading control.
Protein expression of Isg15 in fetal and maternal tissues
Since Ubp43 regulates the conjugation state of Isg15 (free-
or conjugated) we evaluated the influence of increased
Ubp43 mRNA and subsequent Isg15 mRNA in Ubp43 -/-
fetuses on the protein levels of Isg15 in fetal and maternal
tissues. Fetal chorioallantoic placenta were analyzed by
western blot for abundance of Isg15 and conjugated Isg15
proteins. Fetal placental concentrations of Isg15 were
greater (P < 0.05) in null compared to pooled wt and het
fetal-derived tissues on 17.5 dpc (Figure 3). Interestingly,
an interaction occurred where concentrations of conju-
gated Isg15 proteins were greater (P < 0.05) in null CP on
17.5 dpc in contrast to all other genotypes on 12.5 or 17.5
dpc.
To determine if fetal Ubp43 deletion altered levels of free
and conjugated Isg15 in maternal tissues, western blot
analysis was also conducted using MM and AM derived
tissue. Mesometrial tissue had greater (P < 0.05) Isg15 andReproductive Biology and Endocrinology 2007, 5:13 http://www.rbej.com/content/5/1/13
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Northern blot analysis for Ubp43 and Isg15 (panel A) Figure 2
Northern blot analysis for Ubp43 and Isg15 (panel A). Fetal chorioallantoic placental RNA was analyzed for Ubp43 and Isg15 
using cDNA probes. Isg15 mRNA was present on 12.5 and 17.5 dpc in all genotypes. Ubp43 mRNA was present in wt and het 
tissues at the correct size. 18S rRNA was not different. Panel B represents a graphical interpretation of the expression of Isg15 
in fetal chorioallantoic placenta. Isg15 mRNA was greater in null derived placenta in comparison to wt or het placenta. Means 
are LSM ± SE and represent 3 +/+, 3 +/-, and 2 -/- on 12.5 dpc, and 3 +/+, 2 +/- and 2 -/- fetal chorioallantoic placenta. * 
denotes P < 0.07.
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Fetal chorioallantoic placental concentrations of Isg15 Figure 3
Fetal chorioallantoic placental concentrations of Isg15. Panel A represents a western blot of placental free Isg15 (~17-kDa) and 
conjugated Isg15 (> 30-kDa) on 17.5 dpc. Panel B represents quantitation of free placental Isg15. Panel C represents quantita-
tion of conjugated placental Isg15. Null fetal-derived placental tissue had greater concentrations of Isg15 when compared to 
pooled wt/het placenta. An interaction (P < 0.05) of genotype by dpc suggested that null fetal-derived placental tissue had 
greater concentrations of Isg15 conjugates on 17.5 dpc in contrast to other genotypes or null tissue on 12.5 dpc. Means are 
LSM ± SE. * denotes P < 0.05.
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conjugated Isg15 on 12.5 than on 17.5 dpc (Figure 4).
Mesometrial concentrations of Isg15 or conjugated Isg15
did not differ among genotypes (data not shown).
Anti-mesometrial tissue was also analyzed for free Isg15
and its conjugates by western blot. No interactions (dpc ×
genotoype) were observed in AM tissue for free or conju-
gated Isg15, therefore only main effects (dpc or genotype)
are reported. Concentrations of AM Isg15 were greater in
those tissues surrounding null fetuses regardless of dpc
(data not shown). Overall concentrations of Isg15 in AM
tissue were greater (P < 0.05) on 12.5 versus 17.5 dpc (Fig-
ure 5). No differences in conjugated Isg15 were seen
between AM tissues surrounding wt or het fetuses, there-
fore data were pooled. Concentrations of conjugated
Isg15 were greater (P < 0.05) in AM surrounding null
fetuses in contrast to AM encompassing wt and het
fetuses.
Comparison of MM versus AM tissue identified that free
Isg15 was not different (P > 0.05) between the two tissues.
However MM decidua in contact with fetal-derived pla-
centa had greater (P < 0.05) levels of conjugated Isg15 in
contrast to AM tissue (data not shown).
Virological and bacterial analysis of mouse colony
To verify that fetal losses were not due to a compromised
sanitary environment of the animal facility, maternal and
fetal tissues from a Ubp43 heterozygous interbreeding
were tested for a broad spectrum of bacteria and viruses
(Wyoming State Veterinary Diagnostic Laboratory, Lara-
mie, WY) and serum samples collected from a breeding
pair were screened for viruses (Charles River Laboratories,
Wilmington, MA). Both virological and bacteriological
analyses were negative.
Environmental influence of elevation on angiogenic and 
hypoxic markers in the placental compartment
To test if fetal losses were due to the increased elevation of
the facility at UW (approximately 2,183 m; when com-
pared to sea level for the facility at The Scripps Research
Institute), which may alter oxygen tension, fetal and
maternal derived tissues were analyzed by western blot for
various angiogenic markers such as VEGF, angiopoietin-1
and Flt-1 receptor or hypoxia markers such as GLUT-1 and
AMP kinase-1alpha. No differences were seen within tis-
sues based on dpc or genotype for the angiogenic markers
– angiopoietin-1 or Flt-1 receptor or the hypoxic markers.
However in CP tissue, concentrations of VEGF were
greater in null fetal-derived tissue in comparison to
pooled wt/het fetal-derived placental tissues (Figure 6A
and 6B).
Morphological evaluation of placental tissue
Hematoxylin and eosin staining revealed that decidual
and junctional or spongiotrophoblast zones appeared
normal in 12.5 dpc implantation sites from Ubp43 wt
fetuses. Gross evaluation of Ubp43 null mice consistently
showed more densely packed cells within the labyrinth
layer. Also the junctional layer was disrupted, which is not
typical of a mid-gestation placenta. The decidual tissue of
the null-derived placenta had less cellular compaction in
contrast to the Ubp43 wt placenta. Ubp43 heterzygous
fetuses had variable morphology in implantation sites
that was not consistently similar to the wt or the null
fetuses. Complementary characterization of the morphol-
ogy of the junctional zone was performed using immuno-
histochemistry techniques for isolectin B4 (Figure 7,
lower panels). Isolectin B4 has greater specificity for laby-
rinth-derived cells and leaves the junctional zone prima-
rily devoid of stain [40]. Placental tissues derived from
Ubp43 null fetuses had large infarcted areas in contrast to
wt Ubp43 fetal-derived placentas.
Discussion
Endometrial expression of Isg15 occurs during early preg-
nancy in several mammals; including the cow [3], ewe [4],
sow [5] mouse [6,7,20]) and primates [1,20,41]. Inter-
feron-stimulated gene product 15 is hypothesized to play
an intrinsic role during implantation and placentation by
forming an isopeptide bond with intracellular proteins,
potentially altering their activity. An Isg15-specific pro-
tease, Ubp43, is also up-regulated by type I IFNs in a man-
ner that is similar to up-regulation of Isg15 [42].
Therefore, it was postulated that regulation of Ubp43
within the placenta could play a significant role during
pregnancy and fetal development.
Previous reports by our group [6] and others [7] described
increased Isg15 mRNA within AM decidua when com-
pared to deciduoma of psuedopregnant mice on 7.5 dpc.
We also reported that AM decidual Isg15 mRNA increased
from 4.5 to 7.5 and from 7.5 to 9.5 [6]. Expression of
Isg15 mRNA was restricted to maternal tissue and was not
evident in conceptus-derived tissue on 7.5 dpc. [43]. Dur-
ing later stages of pregnancy, MM decidua also expressed
Isg15 and its conjugates on 12.5 and 17.5 dpc regardless
of fetal Ubp43 genotype. The fact that free and conjugated
Isg15 were present through 17.5 dpc in mice may suggest
that not only is Isgylation necessary in the uterus during
early pregnancy, it may also influence placental function,
implantation and fetal development throughout preg-
nancy.
The level of Isg15 within the anti-mesometrial uterine tis-
sue was greater on 12.5 dpc versus 17.5 dpc, which was
similar to the temporal pattern of expression inMM
decidua. However, Isg15 and its conjugates were increasedReproductive Biology and Endocrinology 2007, 5:13 http://www.rbej.com/content/5/1/13
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Mesometrial (MM) concentrations of free Isg15 (A) and conjugated Isg15 (B) Figure 4
Mesometrial (MM) concentrations of free Isg15 (A) and conjugated Isg15 (B). Based on western blot detection of Isg15, MM 
had greater concentrations of Isg15 on 12.5 versus 17.5 dpc (A). MM also had greater concentrations of conjugated Isg15 on 
12.5 dpc in contrast to 17.5 (B). Means are LSM ± SE. * denotes P < 0.05. Arbitrary densitometric units (ADU).
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Anti-mesometrial (AM) tissue concentrations of free Isg15 (A) and conjugated Isg15 (B) Figure 5
Anti-mesometrial (AM) tissue concentrations of free Isg15 (A) and conjugated Isg15 (B). Concentrations of Isg15 determined 
by western blot did not differ across genotype, but were greater on 12.5 dpc in AM tissue than on 17.5. AM concentrations of 
conjugated Isg15 did not differ across dpc. However, AM tissue had increased concentrations of conjugated Isg15 in tissue sur-
rounding null fetuses in contrast to tissue overlying wt/het fetuses. Means are LSM ± SE. * denotes P < 0.05.
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in anti-mesometrial tissue surrounding the null fetuses in
contrast to wild-type or heterozygous fetuses. Increased
anti-mesometrial uterine Isg15 and conjugates surround-
ing null fetuses suggests that fetal deletion of Ubp43 can
influence maternal endometrial levels of conjugated
Isg15, even when tissues are not directly adjacent to one
another.
Isg15 and its conjugates were also present in the vascular
MM tissue surrounding the fetus and this level of expres-
sion was greater when compared to anti-mesometrial tis-
sue on 12.5 and 17.5 dpc. As expected, there was an
increase in conjugated Isg15 in null fetal-derived placental
tissue in contrast to tissue from wild-type and hetero-
zygous fetuses. This was probably caused by an accumula-
tion of Isgylated proteins because of lack of action of the
de-isgylating enzyme through Ubp43 gene deletion.
Increased transcription of the Isg15 gene in response to
Ubp43 -/- is more difficult to explain. However, this might
be an indirect compensatory mechanism because of a lack
of return of conjugated Isg15 to the free pool of Isg15.
Because free Isg15 is essentially consumed, perhaps the
Concentrations of chorioallantoic placental VEGF165 as determined by western blot (panel A) Figure 6
Concentrations of chorioallantoic placental VEGF165 as determined by western blot (panel A). Concentrations of VEGF165 were 
greater in null fetal placenta in comparison to pooled wt/het-derived placenta (panel B). Means are LSM ± SE. * denotes P < 
0.05.
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cell responds to the Ubp43 null by increasing transcrip-
tion of the Isg15 gene in order to continue to provide free
Isg15 that can then enter the conjugating pathway.
Previous researchers have shown that deletion of Ubp43
in knockout mice that survived to term led to accumula-
tion of Isg15 conjugates in the ependymal lining of the
brain, whereas wild-type and heterozygous litter mates
had undetectable levels of conjugated Isg15 proteins [30].
Null mice had an increased incidence of hydrocephalus
and premature death suggesting that Ubp43 has an
important role in postnatal brain development. Under
our conditions we were never able to produce viable
Ubp43 null offspring indicating that Ubp43 deletion may
also play a major role in placental function and/or fetal
development. Ubp43 deficient mice are hypersensitive to
type I IFN and have enhanced and extended IFN signaling
responses that lead towards augmentation of apoptotic
responses [13]. The fetal Ubp43 -/- mice in our study may
have been subjected to increased apoptotic activity as a
result of the type I IFN hypersensitivity. Disregulation of
Isgylation in Ubp43 deficient fetal mice may have caused
fetal death due to enhanced activation of Stat 1 tyrosine
phosphorylation, DNA binding and IFN-mediated gene
activation [13]. Fetal death may also have been due to
non-Isg15 responses such as a lack of direct interaction of
Ubp43 with the IFN receptor [35].
Messenger RNA for Isg15 was increased in Ubp43 deleted
placental tissue as well. Increased expression of Isg15 in
the absence of Ubp43 suggests that Ubp43 may regulate
Isg15 expression directly or have an indirect effect by
influencing the level of free Isg15 within tissues. It is more
likely that the latter is true since previous reports have
indicated that lack of Ubp43 expression enhanced sensi-
tivity to type I IFN signaling and led to increased expres-
sion of interferon-stimulated genes, including Isg15
[13,31,44].
General morphology (hematoxolin-eosin; top panels) and labyrinthe endothelial cell staining (isolectin B4; bottom panels) in  12.5 dpc implantation cross sections Figure 7
General morphology (hematoxolin-eosin; top panels) and labyrinthe endothelial cell staining (isolectin B4; bottom panels) in 
12.5 dpc implantation cross sections. ____ = 200 μm.
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Implantation sites appeared disrupted in Ubp43 null
when compared to wt mice. The junctional zone and the
decidua were less densely compact in Ubp43 null when
compared to wt fetuses. This disregulation of Isg15
through deletion of Ubp43 is hypothesized to contribute
to 75% fetal mortality on day 12.5 of pregnancy.
Vascular endothelial growth factor is upregulated in
response to hypoxia during physiological conditions,
including such events as wound healing [45,46]. Vascular
endothelial growth factor is expressed and localized
within trophoblast cells of various species [47-49] and is
considered to be a very powerful mitogenic and ang-
iogenic factor [50,51]. In vitro studies on VEGF165 incuba-
tion with human trophoblast cells inhibited cell
migration through an extracellular matrix chamber [52].
The increased levels of VEGF165  in the placenta may
inhibit appropriate implantation resulting in fetal mortal-
ity. Albeit, since the mortality rate was 75 and 100% on
12.5 and 17.5 dpc, respectively, the increased VEGF may
be a result of fetal resorption activity or it may have
increased in response to hypoxia. Der and co-workers [42]
reported that VEGF-C mRNA is up-regulated in response
to IFN-α and -γ. Therefore another possible cause for
increased VEGF in null fetal-derived tissue may be an indi-
rect result of increased sensitivity to IFNs due to Ubp43
deletion.
Furthermore Ubp43 -/- mice are hypersensitive to Type I
IFN, implicating a role for Ubp43 to downregulate IFN
responses (Ritchie et al., 2002). These investigators later
identified that Ubp43 attenuated IFN signaling by direct
interaction with the region of the IFNAR2 receptor subu-
nit that interacts with JAK1 [35]. Subsequently interaction
of Ubp43 to the IFNAR2 receptor suppressed JAK1 inter-
actions and concomitantly decreased downstream phos-
phorylation cascades and other IFN-responsive signaling
events. These actions of Ubp43 are independent of its
effects on Isg15.
An expected Mendelian ratio of 1:2:1 wt:het:null live
progeny from het interbreedings of Ubp43 knockout mice
was achieved previously using C57 BL/6 × 129 back-
ground with the pGK-Neo fragment [30]. However, dur-
ing colony expansion we were never able to produce any
viable null offspring at the University of Wyoming (UW)
facility by breeding het (C57 BL/6 × 129 crossed to Swiss
Webster to remove the pGK Neo fragment) pairs. In addi-
tion to loss of null fetuses by 12.5 dpc, we also observed
loss of +/- fetuses by 17.5 dpc. We estimate that the het
animals at the UW facility had less than 50% Swiss Web-
ster genetic contribution.
Ubp43 +/- interbreedings (C57 BL/6 × 129 × Swiss Web-
ster; n = 10 litters) were followed to term, and from these
offspring 16 were +/+ and 31 were +/-, implicating that the
Mendelian ratio for offspring was 1:2 for wt:het, as would
be expected when considering the lack of null offspring.
Therefore, we recorded fetal genotype ratios on 12.5 and
17.5 dpc in utero to investigate the loss of null offspring.
On 12.5 dpc we had a ratio of 2:5:1 from a total of 30 live
and dead fetuses (4 litters). And on 17.5 dpc the ratio was
2:2:1 calculated from 35 live and dead fetuses (6 litters).
On 12.5 dpc only 25% of the null fetuses were viable and
by 17.5 dpc all null fetuses were non-viable. There also
was a noticeable loss of +/- fetuses by 17.5 dpc. The loss of
heterozygous fetuses by 17.5 dpc was unexpected and
might be caused by a Ubp43 gene dosage due to loss of
one allele. When considering live fetuses only, genotypes
did not follow normal expected Mendelian ratios on 12.5
and 17.5 dpc.
The same mice at the Scripps Research Institute produced
Ubp43 -/- mice from heterozygous breedings. At the age
of genotyping (3–4 wks old), a ratio of 1:4:1 from 58 pups
was observed. However, work done at Scripps found that
backcrossing Ubp43 het mice (C57 BL/6 × 129) with C57
BL/6 mice to F10 generation did not produce any viable
Ubp43 -/- pups. Similar to reports by the UW facility,
homozygous Ubp43 null mice died in utero by 12.5 dpc.
It is believed that genetic drift, influenced by the contribu-
tion from C57/BL 6 lineage, altered the outcome at the
UW facility. The founder animals at the UW facility could
have influenced the expressionicity of the +/- interbreed-
ings by either increased genetic contribution from C57
BL/6 or potential deletion of the 129 pGK-Neo fragment
by crossing into the Swiss Webster strain.
Differences in viable offspring due to location may be a
reflection of facility environmental cues. However, bacte-
rial and viral analyses of Ubp43 mice from our facility
were negative suggesting that other causes may be respon-
sible for fetal loss. The slight changes in angiogenic and
hypoxia markers provided preliminary evidence that
hypoxia played a major role in fetal loss, however future
experiments are planned to further study this possibility.
Mouse genetic background and associated genetic modifi-
ers plays a significant role in sensitivity to interferon [53]
and may also explain why fetuses died in the present
experiment, but apparently were born and then died post-
natally in other Ubp43 -/- experiments [30,38]. The
genetic drift due to a mixed background may actually have
caused the unexpected fetal loss.
Conclusion
In summary, we have found that the Isg15 system was
present in maternal and, for the first time reported, in
fetal-placental tissues. As expected, wild-type and hetero-
zygous fetal-derived tissue did not appear to differ or alter
the maternal or fetal Isg15 system. Furthermore, Isg15Reproductive Biology and Endocrinology 2007, 5:13 http://www.rbej.com/content/5/1/13
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mRNA was present through late stages of pregnancy in
fetal tissue. Ubp43 deletion was verified in null fetal tissue
by genotyping and northern blot analysis. And, VEGF was
the only angiogenic marker that was altered by Ubp43
deletion.
Deletion of the Ubp43 gene causes disregulation of the
Isg15 system, a disrupted implantation site and fetal
death in transgenic mice in the present study. This result
is different from reports in the original Ubp43 -/- paper
[30] and from a more recent UBP43/Isg15 double -/-
paper [38] where no impact on reproduction was
reported. However, work done at Scripps revealed that
backcrossing Ubp43 het mice (C57 BL/6 × 129) with C57
BL/6 mice to the F10 generation did not produce any via-
ble Ubp43 -/- pups and these fetuses also died by 12.5
dpc. For this reason, and because the Ubp43 -/- mice are
from different genetic backgrounds, we suspect that there
are strain specific genetic modifiers (not unlike human
populations), that may impact the lethality of deletion of
Ubp43.
Also, the original Isg15 -/- was not described to have any
reproductive problems and also was not described to be
involved with antiviral responses [36]. Since the original
Isg15 -/- report, it has been demonstrated that deletion of
Isg15 does indeed affect antiviral responses and surviva-
bility in response to influenza A/WSN/33 and influenza
B/Lee/40 virus, herpes simplex virus type 1, gammaher-
pesvirus 68 and Sindbis virus infection [54]. Thus, there
are differences in the Isg15 responses due to different
viruses. And even though these investigators report no dif-
ference in reproductive phenotype, there may be strain
differences as just described for the Ubp43 mice in addi-
tion to subtle environmental differences such as mild
hypoxia due to locatioin of the mice. For example, we also
have recently obtained the Isg15 -/- mice from the Knobe-
loch laboratory [38] and have observed a 50% fetal death
rate by 12.5 dpc (our unpublished results), which pro-
vides support for the concept that this reproductive phe-
notype is influenced by genetic background and/or
location.
It is concluded that proper regulation of the Ubp43 and
Isg15 systems are required for fetal viability and develop-
ment. Up-regulation of Isg15 conjugates in Ubp43 null
fetuses may influence cellular responses and signal trans-
duction within maternal and fetal components of the pla-
centa, thereby altering proper implantation or function of
the placental unit. Deletion of Ubp43 causes up-regula-
tion of conjugated Isg15 in null fetuses, which may influ-
ence targeted proteins within maternal and fetal
components of the placenta. Disruption of these target
proteins may influence proper implantation or function
of the placental unit causing deleterious effects on placen-
tation and fetal development in Ubp43 null mice.
Whether the deletion of Ubp43 induces an abnormal
accumulation of conjugated Isg15 which then contributes
to fetal lethality, or this is confounded or pre-empted by
non-Isg15 actions such as Isg15-independent impact of
Ubp43 on the IFN receptor [35] awaits further study.
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